Story
Connect Biopharma Shares Surge on Positive Phase 2 COPD Trial Data
Summary
Connect Biopharma Holdings stock rallied after the company reported highly encouraging topline results from a mid-stage trial of its drug rademikibart for chronic obstructive pulmonary disease (COPD).
Shares of Connect Biopharma Holdings Ltd (CNTB) surged 17.4% to $1.165 in afternoon trading after the company released positive topline data from its Phase 2 trial for rademikibart, a potential treatment for chronic obstructive pulmonary disease (COPD).
Trial Shows High Efficacy
The clinical-stage biopharmaceutical company announced that its Seabreeze STAT trial for rademikibart, an anti-IL-4Rα antibody, met its primary endpoint. The drug was evaluated as an add-on therapy for adult COPD patients with type 2 inflammation who were experiencing acute exacerbations.
According to the company's announcement, the trial demonstrated significant efficacy through the fourth week compared to a placebo. Key results include:
- An 81% reduction in the rate of treatment failure.
- An 85% decrease in new moderate-to-severe COPD exacerbations.
- Complete elimination of new hospital admissions and emergency department visits for new exacerbations.
The safety profile for rademikibart was comparable to placebo, with the treatment group reporting fewer adverse events overall. Following the results, Connect Biopharma announced it plans to discuss Phase 3 development with the U.S. Food and Drug Administration (FDA).
AdAnalyst Reaction and Context
Despite the positive data, some analysts adjusted their outlook. BTIG maintained a Buy rating but lowered its price target on the stock to $5.00 from a previous $10.00. The firm cited a need for more clarity on endpoints for a registrational trial and a potential "cash overhang," pushing its estimated launch timeline to 2030. The company has guided that its current cash runway extends through August 2027.
Overall analyst sentiment remains positive, with a consensus "Moderate Buy" rating from seven analysts and an average price target of $6.14, according to Investing.com data. The strong COPD results provide a significant positive catalyst for the stock, which had recently fallen near its 52-week low following mixed data from an asthma trial in mid-September.
Broader Market Supports Gains
The rally occurred within a constructive market environment. The Nasdaq Composite rose after the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures (PCE) price index, came in cooler than expected. The data reduced investor bets on a near-term interest rate hike, providing a tailwind for growth-oriented sectors like biotechnology.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.
Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.
Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.
Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.